DEPLOYDatabase

Company

Withings

wearablewithings.com

French consumer-health-electronics company (Issy-les-Moulineaux; founded 2008; independent since 2018) of the ScanWatch hybrid analog smartwatches with…

Track Withings
Founded
2008
HQ
Issy-les-Moulineaux, France
Status
private (independent since 2018)

The verified answer

As of Aug 2026, DEPLOY verifies Withings: 1 model, 1 deployment across 1 region, $30.0M raised, 1 active incident. 4 sources back the record.

Regulatory status2 FDA 510(k) clearances

Withings holds 2 FDA 510(k) clearances, per the DEPLOY registry.

See all 2 filings

CategoryBiometric wearables

Funding

$30.0M

Models

1

Deployments

1

Deploy Watch

Track Withings on Deploy.

We notify you when a verified state change lands on the record, not when the company issues a claim.

Track Withings

Regional ecosystem

Withings is one of 77 verified robotics companies in France →

Valuation of record

DEPLOY VERIFIED
$240M (reported, approximate)as of Jul 2026

Priced roundSeries B post-money

See the full valuations ranking →

Key facts

Product

ScanWatch 2 / Nova hybrid analog health watches; ECG/AFib (2021, OTC 2025) + SpO2 FDA-cleared.

Contrast

SpO2/ECG never disabled in US (not in the Masimo dispute); 2025 = positive OTC liberalization.

Company status

Independent since 2018

CEO

Mathieu Letombe

HQ

Issy-les-Moulineaux, France

Total fundingsee investors →

$93.8M across 3 rounds

2025 status

Full year profitability

Revenue growth

~90% since 2019

Data & sources

Press releases

2

Web sources

2

4 sources backing this record.View all →

Models (1)

View all models →

Current platform

Withings ScanWatch

Withings, a French consumer-health-electronics company founded in 2008 and independent again since 2018 after being bought back from Nokia, makes the ScanWatch line of biometric-primary hybrid analog smartwatches with cardiac and respiratory AI augmentation, recorded in the new biometric form factor. The ScanWatch 2 and ScanWatch Nova pair an analog dial with optical heart-rate, electrical ECG, blood-oxygen, and continuous temperature sensors on roughly a 30-day battery. Their FDA clearances are the ECG app, cleared in October 2021 to classify atrial fibrillation, sinus rhythm, and high heart rate for adults 22 and older, updated in July 2025 so that the ScanWatch 2 ECG is cleared over the counter, no longer requiring a board-certified cardiologist to activate, with a new eight-classification atrial-fibrillation algorithm, plus a cleared blood-oxygen feature that supports tracking breathing disturbances at night. A cap-flag applies because the breathing-disturbance detection is a screening aid rather than a sleep-apnea diagnosis, and framing it as diagnosis exceeds scope. Withings offers a clean contrast to Apple, since its blood-oxygen and ECG features were never disabled in the US as it is not party to the Masimo dispute, and the notable 2025 regulatory event was a positive over-the-counter liberalization rather than a restriction. It sells by hardware purchase with an optional Withings+ membership, its clinical-validation posture is substantial for its size with strong study framing and CE medical marking, and the exact clearance numbers and dates for the ScanWatch 2 blood-oxygen and temperature features and the standard US list prices are approximate and not fully verified.

biometricView model →

Withings on the deployment map

View the global map

1 verified deployment across 1 region, newest verified Jun 2024. Explore where Withings's robots are operating, by place and type.

Free to use on your site, with a link back to DEPLOY.

View the full Withings deployment record →

Free to use on your site, with a link back to DEPLOY.

Relationships

WWithingsCustomer

Explainers

Plain-language answers to the questions people ask about Withings, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

What is Withings ScanWatch?
Withings is an independent French biometric wearable company; the ScanWatch line (ScanWatch + ScanWatch 2 + ScanWatch Nova) is the cohort's hybrid analog watch archetype. ECG cleared 2021 EU / OTC 2025 US; SpO2 monitoring across the line. Founded as Withings in France; acquired by Nokia 2016; bought back by founder Eric Carreel 2018; currently independent. Per DEPLOY's biometric cluster framework, Withings anchors the substantial-cleared-for-size archetype: hybrid mechanical-digital design distinct in cohort with cohort-mature peer-reviewed validation depth.Read the full explainer →
How does DEPLOY track the Withings ScanWatch ECG recall?
The Withings ScanWatch FDA Class-2 recall operates as a canonical worked example of incident-tracking at FDA medical-device primary-source verification depth. Per Agent A IncidentStatusEvent substrate at /incidents/withings-scanwatch-ecg-recall-2022 : the U.S. Food and Drug Administration (FDA) issued a Class-2 recall on the Withings ScanWatch ECG feature in 2022. The recall operates at FDA medical-device primary-source verification depth (tier 2 primary-FDA-database per DEPLOY's 9-tier source-quality rubric); the recall sub-tier is structurally distinct from the CPSC consumer-product-safety sub-tier exercised in the Fitbit Ionic burn recall narrative. CRITICAL within-entity verification-state framing: the ScanWatch is a multi-feature device with FDA-cleared ECG + SpO2 (K201456) intersecting with the regulatory recall framing; per verified-vs-claimed at within-entity granularity, the recall affects the ECG feature specifically while other ScanWatch features remained available; the broader Withings entity continues at verified-shipped state across the ScanWatch + ScanWatch 2 + ScanWatch Nova product line. Per DEPLOY's biometric cluster framework, the recall operates within the hybrid analog watch archetype that Withings anchors. This piece documents the catch as framework-in-action worked example: FDA medical-device incident-tracking discipline + within-entity feature-granularity verification-state distribution + multi-tier primary-government-record source-quality demonstration operating at editorial-anchor depth.Read the full explainer →

Current leadership (2)

Founders (3)

See all founders across the registry →

Board (1)

Former / Previously (2)

Safety record

1 recall on record (1 moderate). Most recent: Dec 2022.

moderate
1

Most recent: Dec 2022

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Incidents affecting Withings (1)

Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Operator customers (1)

Recent coverage

Withings in third-party press

Withings acquires Biosency and enters respiratory monitoring space - Health Tech World

Jun 25, 2026

Tech Trends 2026: From AI Assistants to Autonomous Agents - Hounslow Herald

Feb 15, 2026

This hair-thin chip could help cut the link between wearables and phones - Wareable

Feb 3, 2026

Peers

35 peers across 1 segment. Every Withings competitor derived from shared form-factor and application-domain edges.

wearable(35)

32 companies in this segment · highly_concentrated (HHI 2595.3892239124602) · leader Oculus VR at 4361%